Drug intelligence / Profile preview

5-[Bis(2-bromoethyl)amino]-N-(2,3-dioxopropyl)-2,4-dinitrobenzamide

Development stage: Unknown
Modality: Small Molecules

Overview

5-[Bis(2-bromoethyl)amino]-N-(2,3-dioxopropyl)-2,4-dinitrobenzamide is a synthetic small molecule belonging to the class of dinitroanilines. It has a molecular formula of C14H14Br2N4O7 and a molecular weight of approximately 510.09 Da[1][5]. The compound is not approved for clinical use and is classified as experimental[1]. There are no known approved indications or ongoing clinical trials for this molecule as a therapeutic agent[1][3]. Its mechanism of action and pharmacological properties have not been described in publicly available sources.

Other names: 2,4-Dinitro,5-[bis(2-bromoethyl)amino]-N-(2',3'-dioxopropyl)benzamideN-(2,3-dioxopropyl)-2,4-dinitrobenzamide

Beyond the preview

Go deeper on 5-[Bis(2-bromoethyl)amino]-N-(2,3-dioxopropyl)-2,4-dinitrobenzamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-[Bis(2-bromoethyl)amino]-N-(2,3-dioxopropyl)-2,4-dinitrobenzamide.

Explore the full profile